Page 108 - MemoriaCIBER-2017ENG

• Approval and starting to include patients in the MA39293-DIET (MADIET) clinical trial to study the e ect of diet on the adverse gastrointestinal e ects of pirfenidone in idiopathic pulmonary brosis EudraCT number: 2016-003827-45 Sponsor: CIBERES
• Identi cation of acid sphingomyelinase, interleukin -6 and urate crystals as mediators of the pulmonary vascular dysfunction associated with acute pulmonary damage
• Completion of the rst phase of the genomic study of ARDS with 7 8 million genetic variants in 672 patients with sepsis
• Start of recruitment of patients for the Gen-Sep study (Genetics and Biomarkers in Sepsis-in- duced ARDS) to identify biomarkers as candidates for diagnosis and prognosis of ARDS in patients with pulmonary and extrapulmonary origin sepsis
• Identi cation of biomarkers based on microRNAs mir155-3p, miRNA-27a-5p and miRNA- 146a-5p and their modulation by FasL and IL-1β
• Completion of in vitro and in vivo studies of anticoagulant treatment with heparin, anti- throm- bin or antithrombin along with heparin in experimental ARDS
• Final phase of the clinical trial entitled “E ectiveness of dexametasone in treatment of Mod- erately severe persistent Respiratory Distress”
• Completion of the observational study entitled “International Practice Variation in Weaning Critically Ill Adults from Invasive Mechanical Ventilation”
• Analysis of cell therapy with native type II pneumocytes and which overexpress anti-in am- matory genes in a model of acute pulmonary injury
108 CIBER ANNUAL REPORT 2017